论文部分内容阅读
紫杉醇已被证明是广谱的抗肿瘤药物,但因其在水中的溶解度(<0.03 mg/m L)不好,低水溶性给静脉注射用药带来很大困难。许多研究者尝试将紫杉醇制备成脂质体~([1-5]),将难溶于水的紫杉醇包封在药物载体脂质体中,解决紫杉醇溶解性的问题。脂质体作为一种新型的药物传递系统,具有靶向性、缓释性、长效性、无毒、细胞亲和性、可控性等特点~([6-7]),可以增加紫杉醇的溶解度,提高紫杉醇的疗效,降低其毒
Paclitaxel has been shown to be a broad-spectrum antineoplastic drug, but its poor water solubility causes great difficulties for IV administration because of its poor solubility in water (<0.03 mg / mL). Many researchers try to prepare paclitaxel into liposomes [1-5]), the insoluble paclitaxel encapsulated in the drug carrier liposomes, to solve the problem of paclitaxel solubility. As a novel drug delivery system, liposomes have the characteristics of targeting, sustained release, long-acting, nontoxic, cell affinity and controllability [6-7]), can increase paclitaxel Solubility, improve the efficacy of paclitaxel and reduce its toxicity